10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Wednesday, January 13, 2010

Ind-Swift Laboratories Ltd:Buy/sell/hold,growth prospects and recomendation,news and results,target price and analysis,views and outlook

Scripscan:Ind-Swift Laboratories Ltd

Story:Ind-Swift Laboratories Limited manufactures, sells, and exports active pharmaceutical ingredients (API). It offers macrolide antibiotics, including Clarithromycin, Roxithromycin, and Azithromycin in the form of powder/coated granules; cardiovascular products comprising Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel Bisulphate, Clopidogrel Form I, and Ezetimibe; Fexofenadine HCL anti histamine; and Pioglitazone HCL, an anti diabetic product. The company also provides analgesic products consisting of Pentazocine and Pentazocine HCL; Venlafaxine Hydrochloride, an anti depressant product; Ropinirole, an anti Parkinson product; and anti psychotic products, including Quetiapine and Fumarate. Its products under development comprise aromatase inhibitors consisting of Letrozole and Anastrozole; Nitazoxanide, an anti diarrheoal product; Acomprosate Calcium, an alcohol absistence product; and Aripiprazole, an anti psychotic product. The company’s APIs in pipeline consist of Donepezil for Alzheimer’s disease; Fluvastatin for cardiovascular use; Nateglinide, an anti diabetic; Naratriptan, an anti migrane; and Risedronate for osteoporosis. It offers its products in Europe, Asia, Latin America, and the Middle East. Notably, company has started exporting to USA after getting USFDA approval in Sept 2007 for its API manufacturing facility at Derabassi Punjab for Clarithromycin. Presently, exports constitute around 40% of sales with company having presence in 45-50 countries across globe. For future growth the company has a robust product pipeline of 25 products which includes few blockbuster drugs as well. It has successfully filed over 72 DMFs with the US, Canadian, UK and European Drug Authorities. Hence company has been aggressively expanding its capacity and has increased the gross block by almost five times to Rs 470 cr from 100 cr in 2005.With a healthy book value of Rs 97, scrip is trading relatively cheap at a P/E ratio of 5x times.However high debt equity ratio is cause of concern.One can buy the counter at sub 50 levels.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner